Biotechnology · Waltham, Massachusetts, United States
$16.76
-0.30% (-$0.05)2026-07-09
Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$1.2M, 7 sales vs 1 buy)
Revenue$1.0M
Net Income-$23.3M
Market Cap$462.1M
Price Performance
Historical data including institutional events
Company Profile
J
Joshua Brumm
CEO & Executive Director
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics.
The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
